Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 231–240 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 231
- Medicine slug
- caffeine
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 62
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
36%
- Numeric value
- 36
- Unit
- %
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:baf9f88a-776a-44e7-82cc-8f0ca419572f (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
In adults, the mean plasma protein binding in vitro is reported to be approximately 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ef448ca-5549-4272-a6b4-5c4f57653c4c (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
In adults, the mean plasma protein binding in vitro is reported to be approximately 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f423a220-e7bf-4d24-bc52-bafc1864265b (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
In adults, the mean plasma protein binding in vitro is reported to be approximately 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d05ebf4-fd27-3bd1-5634-b41e33abc41f (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
In adults, the mean plasma protein binding in vitro is reported to be approximately 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db4477a3-b291-4b77-9eca-b7ba8f66b2be (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
In adults, the mean plasma protein binding in vitro is reported to be approximately 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc632825-e0a4-4524-8d7d-ce926efab3d6 (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
In adults, the mean plasma protein binding in vitro is reported to be approximately 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bd238d4-4657-4341-9c28-1b468b8f3bf8 (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
In adults, the mean plasma protein binding in vitro is reported to be approximately 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1129235-f7f6-43eb-8d6e-786c14c16f2f (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
In adults, the mean plasma protein binding in vitro is reported to be approximately 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38b39044-737a-4247-a6c4-c86f5e92490e (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
In adults, the mean plasma protein binding in vitro is reported to be approximately 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4fb7c77-1e82-48b7-83c5-dd04ec7c5c4e (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
In adults, the mean plasma protein binding in vitro is reported to be approximately 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d06d3810-9923-4199-be5e-ee5ee086b0a4 (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
In adults, the mean plasma protein binding in vitro is reported to be approximately 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21489401-f2a7-47d3-897a-4b7efa04dd7a (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
In adults, the mean plasma protein binding in vitro is reported to be approximately 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:279a43b8-9ff5-4792-ac19-441f3fa49269 (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
In adults, the mean plasma protein binding in vitro is reported to be approximately 36%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f38c395-0093-4afd-89ec-f96e5dc0934a (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
In adults, the mean plasma protein binding in vitro is reported to be approximately 36%.
Projected row 232
- Medicine slug
- caffeine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 62
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
0.8 to 0.9 L/kg
- Numeric value
- 0.8
- Unit
- L/kg
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:baf9f88a-776a-44e7-82cc-8f0ca419572f (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
The mean volume of distribution of caffeine in infants (0.8 to 0.9 L/kg) is slightly higher than that in adults (0.6 L/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ef448ca-5549-4272-a6b4-5c4f57653c4c (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
The mean volume of distribution of caffeine in infants (0.8 to 0.9 L/kg) is slightly higher than that in adults (0.6 L/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f423a220-e7bf-4d24-bc52-bafc1864265b (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
The mean volume of distribution of caffeine in infants (0.8 to 0.9 L/kg) is slightly higher than that in adults (0.6 L/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5d05ebf4-fd27-3bd1-5634-b41e33abc41f (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
The mean volume of distribution of caffeine in infants (0.8 to 0.9 L/kg) is slightly higher than that in adults (0.6 L/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db4477a3-b291-4b77-9eca-b7ba8f66b2be (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
The mean volume of distribution of caffeine in infants (0.8 to 0.9 L/kg) is slightly higher than that in adults (0.6 L/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc632825-e0a4-4524-8d7d-ce926efab3d6 (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
The mean volume of distribution of caffeine in infants (0.8 to 0.9 L/kg) is slightly higher than that in adults (0.6 L/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bd238d4-4657-4341-9c28-1b468b8f3bf8 (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
The mean volume of distribution of caffeine in infants (0.8 to 0.9 L/kg) is slightly higher than that in adults (0.6 L/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1129235-f7f6-43eb-8d6e-786c14c16f2f (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
The mean volume of distribution of caffeine in infants (0.8 to 0.9 L/kg) is slightly higher than that in adults (0.6 L/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38b39044-737a-4247-a6c4-c86f5e92490e (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
The mean volume of distribution of caffeine in infants (0.8 to 0.9 L/kg) is slightly higher than that in adults (0.6 L/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4fb7c77-1e82-48b7-83c5-dd04ec7c5c4e (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
The mean volume of distribution of caffeine in infants (0.8 to 0.9 L/kg) is slightly higher than that in adults (0.6 L/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d06d3810-9923-4199-be5e-ee5ee086b0a4 (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
The mean volume of distribution of caffeine in infants (0.8-0.9 L/kg) is slightly high‑er than that in adults (0.6 L/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21489401-f2a7-47d3-897a-4b7efa04dd7a (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
The mean volume of distribution of caffeine in infants (0.8 to 0.9 L/kg) is slightly higher than that in adults (0.6 L/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:279a43b8-9ff5-4792-ac19-441f3fa49269 (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
The mean volume of distribution of caffeine in infants (0.8 to 0.9 L/kg) is slightly higher than that in adults (0.6 L/kg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f38c395-0093-4afd-89ec-f96e5dc0934a (opens source in a new tab)
Caffeine label
Version not recorded · Effective date not recorded
The mean volume of distribution of caffeine in infants (0.8 to 0.9 L/kg) is slightly higher than that in adults (0.6 L/kg).
Projected row 233
- Medicine slug
- calcitonin-salmon
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 13
- Source count
- 13
- Agreement rate
- 0.846154
- Recorded readings
66%
- Numeric value
- 66
- Unit
- %
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ece693d8-1832-4b85-8736-819163ba56c1 (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics The absolute bioavailability of calcitonin salmon is approximately 66% and 71% after intramuscular or subcutaneous injection, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0365ebf8-0cb6-49ce-bfde-707d42b9ab00 (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics The absolute bioavailability of calcitonin salmon is approximately 66% and 71% after intramuscular or subcutaneous injection, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26caf31f-7f7c-48a8-a1ac-35d2ceefda2b (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics The absolute bioavailability of calcitonin salmon is approximately 66% and 71% after intramuscular or subcutaneous injection, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb76f8db-9288-4297-9780-f02e3bece9a3 (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics The absolute bioavailability of calcitonin salmon is approximately 66% and 71% after intramuscular or subcutaneous injection, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:753ecc6a-07be-4fc6-9032-cc6ad116a662 (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics The absolute bioavailability of calcitonin salmon is approximately 66% and 71% after intramuscular or subcutaneous injection, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d4507aa-8e10-44a6-bc6e-3176aa8b23cc (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics The absolute bioavailability of calcitonin salmon is approximately 66% and 71% after intramuscular or subcutaneous injection, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26f19d56-44fd-dc7a-46e8-afaaaba5734f (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics The absolute bioavailability of calcitonin-salmon is approximately 66% and 71% after intramuscular or subcutaneous injection, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b8c6917-c217-45bf-a0ac-a2fa0f7d497a (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics The absolute bioavailability of calcitonin-salmon is approximately 66% and 71% after intramuscular or subcutaneous injection, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22f2986f-309c-4133-9e92-1c040453f340 (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics The absolute bioavailability of calcitonin salmon is approximately 66% and 71% after intramuscular or subcutaneous injection, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89cd4f46-b88a-4c10-b25c-47352280dc4e (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics The absolute bioavailability of calcitonin salmon is approximately 66% and 71% after intramuscular or subcutaneous injection, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97a1efc7-ff5a-43e5-bf9c-0d66dbe7e6d9 (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics The absolute bioavailability of calcitonin-salmon is approximately 66% and 71% after intramuscular or subcutaneous injection, respectively.
3%
- Numeric value
- 3
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c82eb602-12e1-692b-d660-f8d5b5736b54 (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
The mean bioavailability of calcitonin salmon nasal spray is approximately 3% of the injectable calcitonin salmon in healthy subjects and, therefore, the conclusions concerning the clinical pharmacology of this preparation may be different.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6eaedb3-5c96-4859-be43-a48c9c818bc7 (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
The mean bioavailability of calcitonin-salmon nasal solution is approximately 3% of the injectable calcitonin-salmon in healthy subjects and, therefore, the conclusions concerning the clinical pharmacology of this preparation may be different.
Projected row 234
- Medicine slug
- calcitonin-salmon
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 13
- Source count
- 11
- Agreement rate
- 0.909091
- Recorded readings
0.15 to 0.3 L/kg
- Numeric value
- 0.15
- Unit
- L/kg
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ece693d8-1832-4b85-8736-819163ba56c1 (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 0.15 to 0.3 L/kg. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Calcitonin salmon is a calcitonin receptor agonist.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0365ebf8-0cb6-49ce-bfde-707d42b9ab00 (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 0.15 to 0.3 L/kg. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Calcitonin salmon is a calcitonin receptor agonist.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26caf31f-7f7c-48a8-a1ac-35d2ceefda2b (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 0.15 to 0.3 L/kg. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Calcitonin salmon is a calcitonin receptor agonist.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb76f8db-9288-4297-9780-f02e3bece9a3 (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 0.15 to 0.3 L/kg. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Calcitonin salmon is a calcitonin receptor agonist.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:753ecc6a-07be-4fc6-9032-cc6ad116a662 (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 0.15 to 0.3 L/kg. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Calcitonin salmon is a calcitonin receptor agonist.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d4507aa-8e10-44a6-bc6e-3176aa8b23cc (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 0.15 to 0.3 L/kg. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Calcitonin salmon is a calcitonin receptor agonist.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26f19d56-44fd-dc7a-46e8-afaaaba5734f (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 0.15 to 0.3 L/kg. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Calcitonin-salmon is a calcitonin receptor agonist.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b8c6917-c217-45bf-a0ac-a2fa0f7d497a (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 0.15 to 0.3 L/kg. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Calcitonin-salmon is a calcitonin receptor agonist.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89cd4f46-b88a-4c10-b25c-47352280dc4e (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 0.15 to 0.3 L/kg. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Calcitonin salmon is a calcitonin receptor agonist.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97a1efc7-ff5a-43e5-bf9c-0d66dbe7e6d9 (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 0.15 to 0.3 L/kg. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Calcitonin-salmon is a calcitonin receptor agonist.
0.15 L/kg
- Numeric value
- 0.15
- Unit
- L/kg
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22f2986f-309c-4133-9e92-1c040453f340 (opens source in a new tab)
Calcitonin Salmon label
Version not recorded · Effective date not recorded
The apparent volume of distribution is 0.15 L/kg to 0.3 L/kg. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Calcitonin salmon is a calcitonin receptor agonist.
Projected row 235
- Medicine slug
- calcitriol
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 27
- Source count
- 22
- Agreement rate
- 1
- Recorded readings
5 to 8 hours
- Numeric value
- 5
- Unit
- hours
- Source records
- 22
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 22 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cdcaffc6-e14e-4607-b77b-fc78a8382f60 (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec93b667-aad2-4e3a-adc6-952f070a0c0a (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c68beb7-1fed-4652-b4e1-672fde0b621d (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26ac6b4d-9576-4710-856b-aca114ea84cf (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8465337c-86ca-ea9d-e053-2991aa0ab167 (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e0574e0-3a41-486a-be37-92ab56b7f81f (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b57feb9f-2c5c-4d1c-9330-09c6e9fed95c (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97cf7807-3b48-403b-bae2-2fe585946e0c (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1fef137-63c5-4662-8cd9-b9e8b12bacb6 (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:626f23d5-31e6-41ca-a696-191a4f2bc7ef (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c40c40c-1627-4bcd-ba35-bee9b952d985 (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34f53d71-78b0-5237-e063-6294a90a2bbd (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38a676c3-c6c6-4008-87df-f32e1cbaba9b (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bdb9c0d4-bdb3-4174-a4d9-55c423f38476 (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bd717a4-5fdf-4697-a6b2-9df55c6517bb (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1fcb1c7-11a9-4a23-a64a-2c8ce9698321 (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:adb1b2d5-33a7-4442-9074-cc1a89966528 (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:554a54a0-3e46-4a9d-8e54-3d853302dbbb (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf621b22-b783-416f-aee3-e0dbfdb782ca (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5c37779-0c26-438f-b1ca-61cf9915d233 (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3289b482-8733-484d-b1db-d7f4cdcd1ac2 (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b48f57a-c023-485d-b846-cab3aaaad486 (opens source in a new tab)
Calcitriol label
Version not recorded · Effective date not recorded
The elimination half-life of calcitriol in serum after single oral doses is about 5 to 8 hours in normal subjects.
Projected row 236
- Medicine slug
- calcium-oxybate
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 6
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
88%
- Numeric value
- 88
- Unit
- %
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5dcf9a5c-312b-420b-82f3-42177d8f9ee4 (opens source in a new tab)
Calcium Oxybate label
Version not recorded · Effective date not recorded
Absorption Following oral administration of sodium oxybate oral solution, GHB is absorbed rapidly across the clinical dose range, with an absolute bioavailability of about 88%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0fb2620-7247-464d-a37a-8b516ce7d563 (opens source in a new tab)
Calcium Oxybate label
Version not recorded · Effective date not recorded
Absorption Following oral administration of sodium oxybate oral solution, GHB is absorbed rapidly across the clinical dose range, with an absolute bioavailability of about 88%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a9e9045-f04d-46eb-8396-2495c6090a31 (opens source in a new tab)
Calcium Oxybate label
Version not recorded · Effective date not recorded
Absorption Following oral administration of sodium oxybate oral solution, GHB is absorbed rapidly across the clinical dose range, with an absolute bioavailability of about 88%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcef2c95-35e9-464d-9025-652acff769e7 (opens source in a new tab)
Calcium Oxybate label
Version not recorded · Effective date not recorded
Absorption Following oral administration of Sodium Oxybate Oral Solution, GHB is absorbed rapidly across the clinical dose range, with an absolute bioavailability of about 88%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:926eb076-a4a8-45e4-91ef-411f0aa4f3ca (opens source in a new tab)
Calcium Oxybate label
Version not recorded · Effective date not recorded
Absorption Following oral administration of Xyrem, GHB is absorbed rapidly across the clinical dose range, with an absolute bioavailability of about 88%.
Projected row 237
- Medicine slug
- calcium-oxybate
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 6
- Source count
- 6
- Agreement rate
- 1
- Recorded readings
0.5 to 1 hour
- Numeric value
- 0.5
- Unit
- hours
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5dcf9a5c-312b-420b-82f3-42177d8f9ee4 (opens source in a new tab)
Calcium Oxybate label
Version not recorded · Effective date not recorded
GHB has an elimination half-life of 0.5 to 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0fb2620-7247-464d-a37a-8b516ce7d563 (opens source in a new tab)
Calcium Oxybate label
Version not recorded · Effective date not recorded
GHB has an elimination half-life of 0.5 to 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10e5e40c-52f3-4c73-8a34-2c29c690a934 (opens source in a new tab)
Calcium Oxybate label
Version not recorded · Effective date not recorded
GHB has an elimination half-life of 0.5 to 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a9e9045-f04d-46eb-8396-2495c6090a31 (opens source in a new tab)
Calcium Oxybate label
Version not recorded · Effective date not recorded
GHB has an elimination half-life of 0.5 to 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcef2c95-35e9-464d-9025-652acff769e7 (opens source in a new tab)
Calcium Oxybate label
Version not recorded · Effective date not recorded
GHB has an elimination half-life of 0.5 to 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:926eb076-a4a8-45e4-91ef-411f0aa4f3ca (opens source in a new tab)
Calcium Oxybate label
Version not recorded · Effective date not recorded
GHB has an elimination half-life of 0.5 to 1 hour.
Projected row 238
- Medicine slug
- canagliflozin
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
65%
- Numeric value
- 65
- Unit
- %
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f76e16f-0c24-454a-81af-4080b312c940 (opens source in a new tab)
Canagliflozin label
Version not recorded · Effective date not recorded
Absorption The mean absolute oral bioavailability of canagliflozin is approximately 65%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9057d3b-b104-4f09-8a61-c61ef9d4a3f3 (opens source in a new tab)
Canagliflozin label
Version not recorded · Effective date not recorded
Absorption The mean absolute oral bioavailability of canagliflozin is approximately 65%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9679460c-55f7-4826-b55c-fe116f020358 (opens source in a new tab)
Canagliflozin label
Version not recorded · Effective date not recorded
Absorption The mean absolute oral bioavailability of canagliflozin is approximately 65%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d5f892b-e4f3-4a9e-9a91-95e2fca34144 (opens source in a new tab)
Canagliflozin label
Version not recorded · Effective date not recorded
Absorption The mean absolute oral bioavailability of canagliflozin is approximately 65%.
Projected row 239
- Medicine slug
- canagliflozin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
10.6 hours
- Numeric value
- 10.6
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f76e16f-0c24-454a-81af-4080b312c940 (opens source in a new tab)
Canagliflozin label
Version not recorded · Effective date not recorded
The apparent terminal half-life (t 1/2 ) was 10.6 hours and 13.1 hours for the 100 mg and 300 mg doses, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9057d3b-b104-4f09-8a61-c61ef9d4a3f3 (opens source in a new tab)
Canagliflozin label
Version not recorded · Effective date not recorded
The apparent terminal half-life (t 1/2 ) was 10.6 hours and 13.1 hours for the 100 mg and 300 mg doses, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9679460c-55f7-4826-b55c-fe116f020358 (opens source in a new tab)
Canagliflozin label
Version not recorded · Effective date not recorded
The apparent terminal half-life (t 1/2 ) was 10.6 hours and 13.1 hours for the 100 mg and 300 mg doses, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d5f892b-e4f3-4a9e-9a91-95e2fca34144 (opens source in a new tab)
Canagliflozin label
Version not recorded · Effective date not recorded
The apparent terminal half-life (t 1/2 ) was 10.6 hours and 13.1 hours for the 100 mg and 300 mg doses, respectively.
Projected row 240
- Medicine slug
- canagliflozin
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
1 to 2 hours
- Numeric value
- 1
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f76e16f-0c24-454a-81af-4080b312c940 (opens source in a new tab)
Canagliflozin label
Version not recorded · Effective date not recorded
Following single-dose oral administration of 100 mg and 300 mg of INVOKANA, peak plasma concentrations (median T max ) of canagliflozin occurs within 1 to 2 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9057d3b-b104-4f09-8a61-c61ef9d4a3f3 (opens source in a new tab)
Canagliflozin label
Version not recorded · Effective date not recorded
Following single-dose oral administration of 100 mg and 300 mg of INVOKANA, peak plasma concentrations (median T max ) of canagliflozin occurs within 1 to 2 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9679460c-55f7-4826-b55c-fe116f020358 (opens source in a new tab)
Canagliflozin label
Version not recorded · Effective date not recorded
Following single-dose oral administration of 100 mg and 300 mg of INVOKANA, peak plasma concentrations (median T max ) of canagliflozin occurs within 1 to 2 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d5f892b-e4f3-4a9e-9a91-95e2fca34144 (opens source in a new tab)
Canagliflozin label
Version not recorded · Effective date not recorded
Following single-dose oral administration of 100 mg and 300 mg of INVOKANA, peak plasma concentrations (median T max ) of canagliflozin occurs within 1 to 2 hours post-dose.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=230Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.